Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT

BACKGROUND: Tumor cell death caused by radiation therapy (RT) triggers antitumor immunity in part because dying cells release adjuvant factors that amplify and sustain dendritic cell and T cell responses. We previously demonstrated that bempegaldesleukin (BEMPEG: NKTR-214, an immunostimulatory IL-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolig, Annah S, Rose, Daniel C, McGee, Grace Helen, Rubas, Werner, Kivimäe, Saul, Redmond, William L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021762/
https://www.ncbi.nlm.nih.gov/pubmed/35444059
http://dx.doi.org/10.1136/jitc-2021-004218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021762/
https://www.ncbi.nlm.nih.gov/pubmed/35444059
http://dx.doi.org/10.1136/jitc-2021-004218

Ejemplares similares